A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
NCT01794143 on ClinicalTrials.gov · last registry update 2026-02-10
An unusually large phase 3: 7,850 participants, more than double the 424 typical for the stage. The sponsor logged completion for 30 April 2021. Primary outcome, as filed: Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- GRADE Study Group
- Sponsor type
- Other
- Enrollment
- 7,850
- Started
- 2013-05
- Primary completion
- 2021-04-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication
Conditions studied
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.